BMS Archives -

Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at

BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast

https://pharmaphorum.com/sales-marketing/bms-catherine-owen-pharma-commercialisation/

Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis

Deep Dive: Communications and Commercialisation

mike.hammerton@pharmaphorum.com BMS, commercialisation, communications, Deep Dive, Deep Dive: Communications and Commercialisation, digital HCP engagement, HCP communication, HCP engagement, patient centricity 0 Comment

The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and

Deep Dive: Communications and Commercialisation

https://pharmaphorum.com/sales-marketing/deep-dive-communications-commercialisation/

Patients/ Views & Analysis/ Views and analysis

Have a chat to help others through loneliness

Catherine Longworth BMS, loneliness 0 Comment

Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s

Have a chat to help others through loneliness

https://pharmaphorum.com/views-and-analysis/have-a-chat-to-help-others-through-loneliness/

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

Market Access/ Oncology/ R&D/ Views & Analysis/ Views and analysis

New Cell & Gene Therapy Collective seeks to boost UK adoption

George Underwood Astellas, bluebird bio, BMS, Cell & Gene Collective, cell and gene therapy, cell therapy, gene therapy, Gilead, Kite, Novartis, UK 0 Comment

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the

New Cell & Gene Therapy Collective seeks to boost UK adoption

https://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/

Digital/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

BMS launches digital Advocacy Exchange for patient groups affected by COVID-19

George Underwood BMS, Bristol-Myers Squibb, coronavirus, COVID-19, Digital Health & COVID-19, Gryt Health, patient groups, patient organisations, Pharma’s Digital Response to COVID-19 0 Comment

Bristol Myers-Squibb and digital health firm GRYT Health have teamed up to develop an ‘Advocacy Exchange’ virtual platform

BMS launches digital Advocacy Exchange for patient groups affected by COVID-19

https://pharmaphorum.com/views-analysis-digital/bms-launches-digital-advocacy-exchange-for-patient-groups-affected-by-covid-19/

Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

ASCO 2020 round-up: Virtual conference still delivers the drama

Richard Staines Amgen, asco, AstraZeneca, BMS, Bristol-Myers Squibb, cancer, CAR T, coronavirus, COVID-19, Keytruda, Kyprolis, Merck & Co, Tagrisso 0 Comment

ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping

ASCO 2020 round-up: Virtual conference still delivers the drama

https://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/

R&D/ Views & Analysis/ Views and analysis

The future of real world evidence

mike.hammerton@pharmaphorum.com BMS, Bristol-Myers Squib, Pfizer, real world data, Real World Evidence, RWD, RWE 0 Comment

Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role

The future of real world evidence

https://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/

News/ News/ Oncology

BMS plans another tack as EU regulators knock back lung cancer combo

Richard Staines BMS, cancer, lung cancer 0 Comment

Bristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line

BMS plans another tack as EU regulators knock back lung cancer combo

https://pharmaphorum.com/news/bms-withdraws-eu-filing-for-opdivoyervoy-in-nsclc/

Views & Analysis/ Views and analysis

2019: the year of the pharma mega-merger

Richard Staines AbbVie, Allergan, Biogen, BMS, Celgene, M&A, Merck & Co, Novartis, Pfizer, Roche, Shire, Takeda 0 Comment

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year

2019: the year of the pharma mega-merger

https://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/

Trending

BMS

Login